Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Inclusion Criteria:

1. Aged 18-75 years;
2. Histologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group \[VALG\] staging system) ;
3. Must sign a written informed consent form prior to any study specific procedures;
4. No prior treatment for ES-SCLC;
5. No more than 5 lesions (including metastases),and at least one measurable lesion that meets RECIST 1.1 evaluation criteria;
6. Life expectancy more than 3 months;
7. ECOG PS 0-1

Exclusion Criteria:

1. Previous treatment with radiochemotherapy for limited-stage small cell lung cancer;
2. Subjects who previously received systemic antitumor or Immune checkpoint inhibitor therapy ;
3. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment;
4. Active brain metastases, Leptomeningeal metastasis(untreated central nervous system (CNS) metastases unless asymptomatic and lesion size\<1cm;
5. Patients with spinal cord compression;
6. Patients with multiple liver metastases(except isolated lesion and lesion size\<2cm);
7. Uncontrollable third cavity effusion (e.g. a large amount of pleural effusion, ascites, or pericardial effusion, etc.) requiring repeated drainage, which was judged by the investigator to be unsuitable for study;
8. The investigator judges that there are any patients who endanger the patient's safety, interfere with the study assessment, and have poor compliance.